CV Sciences, Inc. · OTC:CVSI
CV Sciences — Noblecon 13 Annual Small Cap & Emerging Growth Investor Conference (January 2017)
27 slides from CV Sciences's conference presentation, January 2017
Slide 1: CBD-based Pharmaceutical Development Program
CBD-based Pharmaceutical Development Program Noblecon 13 Annual Small Cap & Emerging Growth Investor Conference January 2017 Symbol: CVSI
Slide 2: Safe Harbor and Disclaimer
Safe Harbor and Disclaimer Safe Harbor: This presentation may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by th
Slide 3: Corporate Overview
Corporate Overview CV Sciences, Inc. • Located in San Diego, CA and Las Vegas, NV • Founded in 2012 • Symbol: CVSI • Two operating divisions: 1) Consumer products 2) Drug development • 40 employees 3 Symbol: CVSI
Slide 4: Trading Snapshot
Trading Snapshot 4 Symbol: CVSI
Slide 5: Drug Development Program Overview
Drug Development Program Overview • CVSI-007 – lead drug candidate • Cannabidiol (CBD) and nicotine combined in gum formulation • Medical Indication – To support cessation of smokeless tobacco use and addiction • Proprietary technology (patent pending) • Seeking 505(b)(2) drug approval pathway 5 Sym
Slide 6: Market Potential
Market Potential No current FDA-approved Estimated Smokeless Tobacco Treatment Market drugs to treat smokeless tobacco use and addiction • There are only 2 smoking $4 Billion cessation FDA-approved drugs – Chantix (Pfizer) and Zyban (GSK) • Until recently, both Chantix $2 Billion and Zyban had “blac
Slide 7: Current FDA-Approved Treatments For Smoking Cessation
Current FDA-Approved Treatments For Smoking Cessation 2015 revenue ≈ $700 million 7 Symbol: CVSI
Slide 8: Unmet Medical Need
Unmet Medical Need Urgent Unmet Medical Need: • Smokeless tobacco is carcinogenic (risk of esophageal, oral and pancreatic cancers). • Smokeless tobacco is one of the most addictive and potent ways of consuming nicotine (an average-size dip in the There are currently mouth for just 30 minutes can de
Slide 9: Epidemic – Smokeless Tobacco Use
Epidemic – Smokeless Tobacco Use Selected Epidemic Statistics: • Serious impact on youth: 5.8% of males 12-17 years of age reported use of smokeless tobacco. • NCAA rules eject both the player and manager for using smokeless tobacco during a game, yet, a 2013 study of 21,000 college athletes found t
Slide 10: Epidemic – Smokeless Tobacco Use
Epidemic – Smokeless Tobacco Use MLB Imposes A Smokeless Tobacco Ban on Future Major Leaguers • New Collective Bargaining Agreement between MLB and the MLBPA agreed to a ban on smokeless tobacco for new major leaguers going forward 10 Symbol: CVSI
Slide 11: Symbol: CVSI
Symbol: CVSI
Slide 12: Tobacco Use Trends
Tobacco Use Trends 250,000 deaths per year 6,000,000 deaths per year Source: Euromonitor International, National Survey on Drug Use and Health Centers for Disease Control and Prevention 12 Symbol: CVSI
Slide 13: Nicotine Addiction Statistics
Nicotine Addiction Statistics • 1 billion smokers worldwide • 40 million smokers in U.S. • 6 million deaths worldwide from smoking, expected to increase to 8 million • 300 million smokeless tobacco users worldwide • 9 million smokeless tobacco users in U.S. • 250,000 deaths worldwide and increasing
Slide 14: Nicotine Addiction Statistics, cont. Financial Impact
Nicotine Addiction Statistics, cont. Financial Impact • $300 Billion+ per year - Direct medical care and lost productivity • Department of Defense reports $1.6 billion per year on tobacco related care, increased hospitalization, and lost days of work Sources: CDC and Tobacco Use and the Military 14
Slide 15: Nicotine + Cannabidiol
Nicotine + Cannabidiol Using patent pending technology, CV Sciences’ drug candidate (CVSI-007) is a chewing gum that combines cannabidiol (CBD) and nicotine to focus on a significant unmet medical need in treating smokeless tobacco use/addiction. NICOTINE + CANNABIDIOL 15 Symbol: CVSI
Slide 16: Nicotine Use & Addiction
Nicotine Use & Addiction Addiction/Dependence • Physical dependence - relaxant, stimulant, increased heart rate and blood pressure, decreased appetite • Emotional dependence - “oral stimulation” of tobacco product used • Mental dependence - nicotine is a mild “antidepressant” 16 Symbol: CVSI
Slide 17: Nicotine PK/PD - Antidepressant
Nicotine PK/PD - Antidepressant • Nicotine reaches the brain in 7-10 seconds • Nicotine is a mild antidepressant • Mechanism of Action: Monoamine Oxidase (“MAO”) Inhibitor • MAO is an enzyme that breaks down dopamine and other “feel good” neurotransmitters that produce pleasure and reward • Lower le
Slide 18: Nicotine Addiction Treatment – Typical Relapse
Nicotine Addiction Treatment – Typical Relapse • No current FDA-approved drugs NRT’s are the most widely used (to treat smokeless tobacco use/ pharmacological product in addiction) treating nicotine addiction. Replacing cigarettes or smokeless • OTC treatments - Nicotine tobacco products with anothe
Slide 19: Proprietary Technology
Proprietary Technology Internal PK/PD research on CBD directly led to our patent pending technology The expanded therapeutic range of combining nicotine and CBD, in a gum format, creates a product that effectively addresses all three nicotine addictions. 19 Symbol: CVSI
Slide 20: Breaking Nicotine Addiction
Breaking Nicotine Addiction Successfully treating nicotine NICOTINE addiction with Nicotine/CBD combination drug product CVSI-007 provides a therapeutic range that provides effective flexibility in treating the addiction rather simply replacing one nicotine product for another 1. Nicotine – physical
Slide 21: Target Market
Target Market Smokeless Tobacco Market Estimated Smokeless Tobacco Treatment Market • Approximately $5.3 billion annual US retail sales of smokeless tobacco products. $4 Billion • Approximately 9 million Americans use smokeless tobacco with enormous and growing worldwide use. $2 Billion • $2 billion
Slide 22: Development Pipeline
Development Pipeline (*) Seeking 505(b)(2) regulatory pathway 22 Symbol: CVSI
Slide 23: Recent Addiction Cessation Valuation
Recent Addiction Cessation Valuation 23 Symbol: CVSI
Slide 24: Compelling Valuation
Compelling Valuation Several companies developing CBD based products currently have a significantly higher market capitalizations. As CVSI-007 advances into clinical development during 2017, significant shareholder value could result. 24 Symbol: CVSI
Slide 25: Key Points
Key Points Rationale • Pursuing large market opportunities with unmet medical needs • Smokeless tobacco treatment market is ≈ $2.0b, growing to $4b+ • No current FDA-approved drugs for treatment • Treatment options – NRTs & two “Black Box” warning drugs • Surgeon General – “An Epidemic” • Proprietar
Slide 26: Contact
Contact CV Sciences, Inc. Media and Investor Relations Joseph Dowling, CFO IRTH Communications Tel: 866-290-2157 Robert Haag, Managing Director joseph.dowling@cvsciences.com Tel: 866-976-4754 cvsciences.com CVSI@irthcommunications.com 26 Symbol: CVSI
Slide 27: References
References http://www.pfizer.com/system/files/presentation/2015_Pfizer_Financial_Report.pdf http://marketrealist.com/2016/10/chantix-expected-boost-pfizers-revenues-2016/ http://www.fool.com/investing/general/2014/01/27/are-smoking-cessation-drugs-better- than-nicotine-b.aspx http://www.forbes.com/s